[Benefits of home-based administration of palivizumab in high-risk groups]
{{output}}
Palivizumab, a humanized monoclonal antibody against the respiratory syncytial virus (RSV), currently is indicated in groups at higher risk of developing severe RSV disease, such as extreme premature infants and patients with hemodynamically significant heart ... ...
